Navigation Links
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
Date:5/16/2008

- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate the Strength of VELCADE Combinations in Front-line Multiple Myeloma -

CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced that new data from VELCADE clinical studies are scheduled to be featured at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 30 - June 3, 2008. The data will highlight the significant efficacy of multiple VELCADE based therapies in patients with newly diagnosed multiple myeloma (MM).

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The Company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in December 2007 for the use of VELCADE to treat patients with newly diagnosed MM. The filing is based on data from the landmark Phase III VISTA trial. The FDA granted the sNDA priority review and a decision is expected by June 20, 2008. VELCADE is currently the market leader in relapsed multiple myeloma and the only drug approved for the treatment of relapsed mantle cell lymphoma.

"VELCADE based therapies continue to demonstrate unprecedented complete remission rates and survival benefits for patients with newly diagnosed multiple myeloma," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "Data to be presented at ASCO are expected to support that deep and durable complete remissions are an important indicator for long-term patient outcomes. The continued strength of clinical trial data, combined with the pending FDA approval, will further solidify VELCADE as a key component of the standard of care for this disease."

Newly Diagnosed Multiple Myeloma

Data to be featured at ASCO include the use of VELCADE in both newly diagnosed transplant and non-transplant MM patients. The da
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
2. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
3. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
4. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
5. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
6. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
7. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
9. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...., Nov. 9 Anesiva, Inc. ...5, 2009, it received a letter from The NASDAQ Stoc...aring Panel has granted Anesiva,s request for cont...to the condition that Anesiva shall have completed...er (the "Merger") contemplated by the Agreement an...
(Date:11/9/2009)...PRNewswire-FirstCall/ -- Caliper Life Sciences, In...nd services for drug discovery and life sciences r...y Alliances and Services (CDAS) unit has been awar...r its contract with the Environmental Protection A...m. This new task order increases the cumulative f...
(Date:11/7/2009)... Most patients with hereditary angi...n oncoming HAE attack giving the patients sufficie...bidity associated with that attack, according to s...n College of Allergy, Asthma & Immunology (ACA...such as fatigue and nausea, which occur frequently...
Breaking Medicine Technology:Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 3Caliper Awarded New Task Order for EPA ToxCast Program 2Caliper Awarded New Task Order for EPA ToxCast Program 3Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3Chicago Hispanic Health Coalition Presents Third Annual Vive tu Vida 21 Get Up 21 Get Moving 21 28TM 29 Event 49009 1Chicago Hispanic Health Coalition Presents Third Annual Vive tu Vida 21 Get Up 21 Get Moving 21 28TM 29 Event 49009 2Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference 12643 1Study Demonstrates Efficacy of Pitavastatin in Elderly Patients 4598 1Study Demonstrates Efficacy of Pitavastatin in Elderly Patients 4598 2Study Demonstrates Efficacy of Pitavastatin in Elderly Patients 4598 3
... China, Sept. 3 Simcere,Pharmaceutical Group (NYS...branded generic pharmaceuticals and manufacturer o...lso known as Endostar) in China,announced the inte...the request of the SFDA, Simcere initiated a Phase...and therapeutic efficacy of Endu, a modified,versi...
...BURG, Md., Sept. 3 Panacea Pharmaceuticals,Inc. t...7,413,737 covering,antibodies against human aspart...etary human cancer biomarker and therapeutic targe...n with the Massachusetts Institute of,Technology (...o this patent,for development of human cancer diag...
Other Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4
(Date:11/9/2009)... Networking is everybody,s buzz word tod... StaffingClub.com enables Recruiters and Staffers ...nnect, share, communicate and close positions. The...their profiles and network with recruiters. , ...urrent Job Market forces everyone to network more ...
(Date:11/9/2009)...lans finds differences in mood despite similar wei...ews) -- Both a high-fat, low-carbohydrate diet suc...h-carb diet appear to help people lose pounds over... the low-fat diets will result in long-term improv...issue of Archives of Internal Medicine . , Peo...
(Date:11/9/2009)... China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Tr...unced today that Novartis, a US$41 billion interna...ke in HTDS, H1N1 Vaccine partner, Zhejiang Tianyua.... Novartis of Switzerland will begin a five-year, ...pany will dramatically increase its investment in ...
(Date:11/9/2009)... Course, to be Offered in April 2010, Pr... Cambridge, MA (Vocus) Nov... for Human Rights (PHR) first inspected a suspecte... realized he would need a team of experts to help ...site properly was a key first step in securing evi...
(Date:11/9/2009)...ICA, Calif., Nov. 9 Actress Marisk...ned philosophy on Saturday to raise awareness ...ces throughout California by building healing and ...h kits were created to give one to each of the est...Los Angeles County,s domestic violence shelters. ,...
Breaking Medicine News(10 mins):Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3
...r courses are available in condensed format at 15 ...ssionals gain new knowledge and improve skills , ...Pennsylvania now have even more options to receive...am, to include timely, relevant topics, such as he...
...RANCISCO, March 9 Medivation, Inc. (Nasdaq: M...nference and webcast with management to discuss fo...nd provide a general business update on Monday, Ma...on March 16, 2009. , , Interested parties may ca...
...BURGH, March 9 In Kentucky, nearly one out of e...edicaid, but barely a quarter of the dentists acce...re left with few options when it comes to seeing a...has donated 10,000 toothbrushes and 30,000 tubes o...
...ity of care, closure important for dying, families...9 (HealthDay News) -- When there,s no more that ca...us of care turns to keeping them comfortable befor...lpful for all concerned, and it helps provide a se...
...ng Up Top Athlete Endorsers, Myo-Med Makes Expo Sp... a name? For the fledgling pain relief brand Myo-M...nian Tomlinson, Willie McGinest and Lisa Leslie ar..., these athletes actually used the product for a c...
...ILLE, Pa., March 9 West Pharmaceutical Services, ... Morel, Jr., Ph.D., Chairman and Chief Executive O...cer, will be presenting at the 2009 Barclays Globa...tor link of the Company,s website at www.westphar...
Other Medicine News:Health News:Penn State Expands Professional Development Program for School Nurses, Now in its Seventh Year 2Health News:Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009 2Health News:GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia 2Health News:Dying Feel Abandoned by Docs in the End 2Health News:Dying Feel Abandoned by Docs in the End 3Health News:Tom Brady Endorsed Pain Cream Returns to Natural Products Expo 2
MBS Thermal Cycler 1 Block Start Up Kit
...Thermal Cycler (PxE) is a licensed 96 well PCR mac...s for value for money thermal cycling. It is buil...rience in manufacturing and retains a high level o... other products in the range. The combination of ...
MyCycler Thermal Cycler
GeneAmp PCR System 2700
Medicine Products: